To determine whether this subgroup of patients could benefit from a CDK7 targeting approach, we analysed the expression of CDK7 in 18 PTCL-NOS and 17 ALCL-ALKneg cases. The gene discussed is CDK7; the disease is anaplastic large cell lymphoma.